A novel series of milbemycin antibiotics were isolated from the fermentation broth of a Streptomyces species designated E225. The structures of the four main metabolites VM44857 (1), VM44864 (2), VM44865 (3) and VM44866 (4) were determined by NMRtechniques. In addition wedescribe the solution conformations of the major metabolite VM 44857(1).
In a previous paper1} a novel Streptomyces species designated E225 and the anthelmintic activity of four of the milbemycin metabolites produced by this organism were described. In this paper we describe the structure elucidation of these metabolites which are related to other knownmilbemycinsbut are unusual in possessing an unsaturated C-25 side chain and being either unsubstituted at C-22 and C-23 or possessing a single C-22-hydroxyl group instead of the more common C-23-hydroxyl substitution.
Materials and Methods

Fermentati on
The seed medium consisted of (all concentrations in g or ml/litre): Special peptone (Oxoid) 2.5, beef extract (Oxoid Lab. Lemco) 2.5, Tryptone (Oxoid) 2.5, Neutralised soya peptone (Oxoid) 2.5, soluble starch (BDH) 2.5, glucose 2.5, malt extract (Oxoid) 2.5, glycerol 2.5 and trace elements solution 5. The composition of the trace elements solution was (all concentrations in g/litre): CaCl2-2H2O10, MgCl2-6H2O 10, NaCl 10, FeCl3 3, ZnCl2 0.5, CuCl2-2H2O 0.5, MnSO4-4H2O 0.5 and CoCl2-6H2O 1.
Seed medium (50ml) in 250-ml Erlenmeyer flasks was inoculated with Streptomyces species E225 by addition of small areas of growth cut from an agar plate. Flasks were incubated at 27°C for 48 hours on a gyratory shaker at 240 rpm.
The production medium consisted of (all concentrations in g or ml/litre): Soluble starch (BDH)20, casein (Sigma) 2, soyabean flour (Arkasoy 50) 10, glucose 20, calcium carbonate 5, magnesium sulfate (MgSO4-7H2O) 1, casein hydrolysate 2, K2HPO40.5 and trace element solution 10. Production medium (50 ml) contained in 250-ml Erlenmeyer flasks was inoculated with 2 ml of the seed, and incubated at 27°C on a gyratory shaker at 240rpm.
During the fermentation, samples were removed, treated with an equal volume of acetone, filtered and the filtrate assayed by HPLC(Ultrasphere ODS5 jLtm column 25 cm x 4.6mm, eluted with 90 : 10 methanolwater at 1 ml/minute monitored by UVabsorption at 246 nm) to determine optimum time for harvest. After 13 days, the whole broth from 200 flasks was combined and centrifuged.
These milbemycin metabolites were reported in Eur. Pat. Appl. 254, 583 published Jan. 27, 1988. Instrumental *H and 13C NMRspectra were recorded at ambient temperature, in a 5-mm*H/13C dual probe on a Briiker AM400spectrometer using standard software. The 2D *H COSY-45 NMRspectra2) for 1 to 4 were acquired using 16 or 32 scans for each of 512 x 2K FID's. The FID matrix was zero-filled to 2K x IK prior to double FT. The 2D !H,13C COSYNMRspectra for 1 and 2 were acquired with !H decoupling in both dimensions2) and were tuned for 1JCh= 140Hz, with 64 scans for each of 256 x4K FID's. The 2D 'H^C COLOCNMRspectrum2) of 3 was tuned for VCH=9.5 Hz and acquired with 800 scans for each of 240 x 4K FID's. The compounds were dissolved in CDC13. HR-MSdata were obtained using a VGAnalytical ZAB-IF instrument.
Results and Discussion
The metabolites were detected using an in vitro assay measuring activity against the nematode Haemonchuscontortusl\ and the HPLCmethod described above.
Isolation
The cell mass was slurried in water (0.75 litre), stirred with acetone (1.0 litre) for 30 minutes and filtered through Hyflo supercel (BDH Chemicals Limited). The residue was washed with acetone (3 x 1 litre) and the combined filtrates were evaporated to remove the acetone. The aqueous residue (600 ml) was extracted with chloroform (4 x 500 ml), the combined chloroform extracts dried (MgSO4) and evaporated to yield a brown oil (6g). The oil was applied to a short silica column (lOOg) and the column eluted sequentially with 200ml volumes ofhexane-ether mixtures of the following compositions (1 : 0, 3 : 1, 1 : 1, 1 : 3 and 0 : 1). The bulk of the milbemycin metabolites were contained in the last two fractions which were evaporated to yield white solids (356 and 522mg, respectively).
These two solids were separately chromatographed on silica (75 g) eluted with 0-100% ether in hexane and the fractions monitored by HPLC. The fractions containing VM44857 (1), VM44864 (2) and VM44865 (3) were evaporated to yield the pure metabolites (280, 107 and 1 1 mg, respectively) as white amorphous solids. The fractions containing VM44866 (4) were further purified by preparative TLC on silica gel taper plates (Analtech) eluted with 5%methanol in dichloromethane to yield pure VM44866 (4) (6mg) as a white amorphous solid.
Structure and Solution Conformations of VM44857 (1) The metabolite VM 44857 (1), possessed a UV AjJa^nm (a) 224 (31,300) suggesting a conjugated diene, [a]" +111-2°(c 0.25, acetone) and the mass spectrum gave a molecular ion (m\z 568.3412) corresponding to a molecular formula C34H48O7. The 13C NMRspectrum exhibited 34 resonances and was very similar to that reported3) for milbemycin D (5), with the signals for the macrocyclic ring system C-l to C-30 all within 0.8 ppmwith the exception of C-25. This suggested that VM44857 was a milbemycin related to milbemycin D (5), with a different substituent at C-25. The *H and 13C NMRspectra (Table 1) were assigned using 2D lK COSY-45 and 2D 'H^C COSY experiments and the structure for VM44857 shown to be 1, which is unsubstituted at both C-22 and C-23, similar to milbemycin D (5), and possessing an unsaturated C-25 side chain. The same C-25 side chain has recently been reported4) to occur in another natural milbemycin (6) although this milbemycin, unlike VM 44857 (1), possesses an axial C-23-hydroxyl group. The assignment of the 13C NMRspectrum for VM44857 (1) is in complete agreement with that reported20 for milbemycin D (5) for C-l to C-30 and contrary to a recent suggestion5) concerning the spectral c S=small (0~2%), M=medium (2~5%), L=large (>5%).
assignments for milbemycin D (5), the 2D !H,13C COSYand 2D !H COSY-45 NMRspectra, Figs. 2 and 3 , respectively, clearly show that the signal for C-17 is at higher field than that for C-19. The apparent reversal5* of the relative positions of the C-17 and C-19 signals in the related milbemycin (6) is possibly caused by the effect of hydrogen bonding between the axial 23-hydroxyl group, present in this particular metabolite, and O-17 affecting the shielding at C-17. The presence of hydrogen bonding between the 23ax-hydroxyl group and O-17 has been observed6) in the X-ray structure of a closely related metabolite. Using !H NOEdifference spectroscopy experiments it was also possible to compare the solution state conformation of VM44857 (1) with the solid state conformation of a related milbemycin (7) for which X-ray crystallographic data are available6). Hydrogenatoms were added to the X-ray structure using standard bond lengths and angles for each atom type and the distances between adjacent protons measured. Overall 67 NOE's (Table 1 ) were observed in the NOEdifference spectroscopy experiments and of these 57 corresponded to protons less than 3.1A apart in the modified crystal structure of 7. A further 9 NOE's were very small ( < 0.6% enhancement) and were attributed to longer range interactions with relatively isolated protons. Structures of VM 44864 (2), VM 44865 (3) and VM 44866 (4) The structures of the other three milbemycin metabolites VM44864 (2), VM44865 (3) and VM44866 (4) were deduced by analysis of their respective ID and 2D *H and 13C NMRspectra (Table 2 and 3) in the light of the unambiguous assignments obtained for VM44857.
VM44864 (2) and VM44866 (4) were obviously structurally related on the basis of their 13C NMR spectra. Analysis of the^-'H connectivities in the 2D *H COSY-45 NMRspectrum of VM44866 (4) gave a similar connectivity map to VM44857 (1), except that the spectrum indicated that C-22 was hydroxylated. This was consistent with the mass spectral data which gave a molecular ion (m/z 584.3335) corresponding to a molecular formula of C34H48O8. The observation of 23-Hax as a high field quartet (2J23,22^3J23,24^^23,23 close similarity between the *H and l3C spectra of VM44864 (2) and VM44866 (4), with the exceptions of 5-H and 6-H and C-5 and C-6, lead to the conclusion that VM44864 (2) was the 5-methoxy derivative of VM44866 (4) . Additional physico-chemical data was recorded as follows: SEPT. 1990 VM 44866 (4) The mass spectrum of VM44865 (3) gave a molecular ion (m\z 696) corresponding to a molecular formula of C^s^Aq. Both the *H and 13C spectra indicated that 26-CH3 was absent and the 13C spectrum showed a new CH2signal at 64.3 ppm. In addition, the *H NMRspectrum showed a new set of resonances corresponding to a second dimethylvinyl residue and the 13C spectrum showed the presence of a new ester carbonyl group. Comparison of the *H and 13C spectra with those for the other metabolites indicated that this was a 22-hydroxy-5-methoxy derivative and it was therefore deduced that it was oxidatively functionalised on 26-CH3 with a 2-methylbut-2-enoate moiety. The structure of VM44865 (3) was conclusively confirmed by the results of a 2D^"C COLOCexperiment which showed connectivities from C-26 to 3-H and from C-35 to 39-H and 26-Hb. The stereochemistry of the 2-methylbut-2-enoate moiety was confirmed as E on the basis of the absence of an NOEbetween 37-H and 39-H. VM44864 (2), VM44865 (3) and VM44866 (4) are particularly interesting in that they all possess an equatorial hydroxyl group at C-22, unlike the more commonC-23 axial hydroxy compounds. Only one previous milbemycin has been reported7* which possesses a 22 hydroxy-23-dihydro functionality although a number of 22,23-dioxygenated milbemycins are known8), and, as we have previously shown9), at least some of these have diequatorial stereochemistry at C-22 and C-23.
